Lacosamide
- Generic Name
- Lacosamide
- Brand Names
- Motpoly, Vimpat, Lacosamide Adroiq, Lacosamide Accord, Lacosamide UCB
- Drug Type
- Small Molecule
- Chemical Formula
- C13H18N2O3
- CAS Number
- 175481-36-4
- Unique Ingredient Identifier
- 563KS2PQY5
- Background
Lacosamide is a functionalized amino acid that has activity in the maximal electroshock seizure test, and is indicated for the adjunctive treatment of partial-onset seizures and diabetic neuropathic pain. Recent studies indicate that Lacosamide only affects those neurons which are depolarized or active for long periods of time, typical of neurons at the focu...
- Indication
Lacosamide is indicated for the treatment of partial-onset seizures in patients aged one month and older and as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients aged four years and older.
- Associated Conditions
- Epilepsy, Primary Generalized Tonic-Clonic Seizures, Partial-Onset Seizures, Status Epilepticus
- Associated Therapies
- -
STTEPP: Safety, Tolerability and Dose Limiting Toxicity of Lacosamide in Patients With Painful Chronic Pancreatitis
- First Posted Date
- 2022-11-03
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Indiana University
- Target Recruit Count
- 24
- Registration Number
- NCT05603702
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
🇺🇸Indiana University, Indianapolis, Indiana, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Acute Sympotomatic Seizure Secondary to Autoimmune Encephalitis and Autoimmune-associated Epilepsy
- Conditions
- First Posted Date
- 2022-06-16
- Last Posted Date
- 2023-07-14
- Lead Sponsor
- Liu Yonghong
- Target Recruit Count
- 500
- Registration Number
- NCT05422664
- Locations
- 🇨🇳
XijingH, Xi'an, Shaanxi, China
Lacosamide in Neonatal Status Epilepticus
- First Posted Date
- 2022-03-22
- Last Posted Date
- 2022-03-22
- Lead Sponsor
- Sherief Abd-Elsalam
- Target Recruit Count
- 60
- Registration Number
- NCT05291455
- Locations
- 🇪🇬
Kafrelsheikh University, Tanta, Kafrelsheikh, Egypt
A Real World Study on the Efficacy and Safety of Lacosamide as Add-on Therapy for Focal-onset Epilepsy
- Conditions
- Interventions
- First Posted Date
- 2021-02-04
- Last Posted Date
- 2021-02-04
- Lead Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- Target Recruit Count
- 200
- Registration Number
- NCT04737837
- Locations
- 🇨🇳
The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China
🇨🇳The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
🇨🇳Shenzhen Children's Hospital, Shenzhen, Guangdong, China
A Study to Test the Long-term Use of Oral Lacosamide in Pediatric Study Participants Who Completed NCT01964560 (EP0034) or NCT00938912 (SP848) and Received Lacosamide Treatment
- First Posted Date
- 2020-11-13
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 48
- Registration Number
- NCT04627285
- Locations
- 🇺🇦
Ep0151 606, Kiev, Ukraine
🇬🇪Ep0151 620, Tbilisi, Georgia
🇺🇦Ep0151 682, Uzhgorod, Ukraine
Evaluation of the Efficacy and Safety of Lacosamide in Pediatric Patients With Epilepsy
- First Posted Date
- 2019-10-30
- Last Posted Date
- 2020-05-12
- Target Recruit Count
- 300
- Registration Number
- NCT04144218
- Locations
- 🇨🇳
Department of Nuclear Medicine and PET/CT Center, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
The Effect of Lacosamide in Peripheral Neuropathic Pain
- Conditions
- Interventions
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2023-02-16
- Lead Sponsor
- Danish Pain Research Center
- Target Recruit Count
- 63
- Registration Number
- NCT03777956
- Locations
- 🇩🇰
Danish Pain Research Center, Aarhus University Hospital, Aarhus, Denmark
Pharmacokinetics of Antiepileptics in Patients on CRRT
- First Posted Date
- 2018-08-16
- Last Posted Date
- 2021-10-05
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 18
- Registration Number
- NCT03632915
- Locations
- 🇺🇸
University of Maryland Medical Center, Baltimore, Maryland, United States
Compassionate Use Program With Lacosamide in Patients With Partial-onset or Generalized Tonic-clonic Seizures
- Conditions
- First Posted Date
- 2018-06-18
- Last Posted Date
- 2019-10-31
- Lead Sponsor
- UCB Biopharma S.P.R.L.
- Registration Number
- NCT03559673
Seizure Prophylaxis in Patients With Glioma or Brain Metastasis
- Conditions
- Interventions
- First Posted Date
- 2018-02-19
- Last Posted Date
- 2023-04-13
- Lead Sponsor
- Duke University
- Target Recruit Count
- 4
- Registration Number
- NCT03436433
- Locations
- 🇺🇸
Duke Comprehensive Cancer Center, Durham, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.